In AD models of tau P301S and 5XFAD mice, 3-month chronic treatment with δ-secretase inhibitor 11 significantly reduced tau cleavage and Aβ deposition, and ameliorated impairment in the structural and functional plasticity of synapses [48]. Here, MAPT is linked to Alzheimer disease.